INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION

Adverse reaction reported in 108,560 FDA reports across 50 drugs.

108,560
Total Reports
50
Drugs Involved
Dupilumab
Most Reported Drug

Drugs Associated with INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION

Drugs where "INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION" was reported as an adverse event.

# Drug Reports % of Total
1 Dupilumab 17,346
16.0%
2 Adapalene 16,217
14.9%
3 Insulin Glargine 9,976
9.2%
4 Infliximab-Dyyb 6,227
5.7%
5 Secukinumab 4,940
4.6%
6 Salicylic Acid 4,808
4.4%
7 Vedolizumab 3,895
3.6%
8 Dulaglutide 3,831
3.5%
9 Diphenhydramine 3,038
2.8%
10 Sacubitril / Valsartan 2,677
2.5%
11 Semaglutide 2,654
2.4%
12 Mesalamine 2,122
2.0%
13 Octreotide 1,940
1.8%
14 Epinephrine 1,919
1.8%
15 Cabozantinib 1,846
1.7%
16 Mepolizumab 1,819
1.7%
17 Adrenalinum 1,723
1.6%
18 Human Immunoglobulin G 1,549
1.4%
19 Nemolizumab-Ilto 1,431
1.3%
20 Lidocaine 1,332
1.2%
21 Minoxidil 1,167
1.1%
22 Ofatumumab 980
0.9%
23 Canakinumab 954
0.9%
24 Guselkumab 942
0.9%
25 Fluticasone Furoate, Umeclidinium Bromide / Vilanterol Trifenatate 855
0.8%
26 Buprenorphine Hydrochloride, Naloxone Hydrochloride 784
0.7%
27 Lisdexamfetamine Dimesylate 769
0.7%
28 Bimekizumab 766
0.7%
29 Nirmatrelvir / Ritonavir 750
0.7%
30 Linaclotide 739
0.7%
31 Minoxidil Foam 5% (Womens) 728
0.7%
32 Paliperidone Palmitate 716
0.7%
33 Belimumab 685
0.6%
34 Ixekizumab 673
0.6%
35 Benralizumab 569
0.5%
36 Teduglutide 537
0.5%
37 Sulfur 455
0.4%
38 Polyethylene Glycol 400 450
0.4%
39 Instalax Polyethylene Glycol 3350 442
0.4%
40 Polyethylene Glycol (3350) 442
0.4%
41 Tolvaptan 428
0.4%
42 Docosanol 399
0.4%
43 Glycerin, Lidocaine 388
0.4%
44 Fremanezumab-Vfrm 325
0.3%
45 Trifluridine / Tipiracil 306
0.3%
46 Cabotegravir 246
0.2%
47 Lanreotide 242
0.2%
48 Methoxy Polyethylene Glycol-Epoetin Beta 198
0.2%
49 Rimegepant 176
0.2%
50 Eptinezumab-Jjmr 159
0.1%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. The presence of a drug in this list does not mean the drug caused inappropriate schedule of product administration. Always consult your healthcare provider.